IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 381 filers reported holding IONIS PHARMACEUTICALS INC in Q4 2020. The put-call ratio across all filers is 0.43 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,344 | +5.3% | 29,618 | -4.8% | 0.01% | +25.0% |
Q2 2023 | $1,276 | +9.5% | 31,103 | -4.6% | 0.00% | -20.0% |
Q1 2023 | $1,165 | -6.7% | 32,608 | -1.4% | 0.01% | 0.0% |
Q4 2022 | $1,249 | -99.9% | 33,058 | +2.0% | 0.01% | -16.7% |
Q3 2022 | $1,434,000 | +26.3% | 32,415 | +5.7% | 0.01% | +20.0% |
Q2 2022 | $1,135,000 | -20.6% | 30,658 | -20.6% | 0.01% | -16.7% |
Q1 2022 | $1,430,000 | +29.1% | 38,614 | +6.0% | 0.01% | +50.0% |
Q4 2021 | $1,108,000 | -3.2% | 36,424 | +6.6% | 0.00% | -20.0% |
Q3 2021 | $1,145,000 | -25.7% | 34,153 | -11.6% | 0.01% | -28.6% |
Q2 2021 | $1,542,000 | -6.8% | 38,646 | +5.0% | 0.01% | -12.5% |
Q1 2021 | $1,655,000 | -18.6% | 36,812 | +2.3% | 0.01% | -20.0% |
Q4 2020 | $2,034,000 | +14.7% | 35,973 | -3.8% | 0.01% | 0.0% |
Q3 2020 | $1,773,000 | -21.8% | 37,375 | -2.8% | 0.01% | -28.6% |
Q2 2020 | $2,266,000 | +19.9% | 38,434 | -3.9% | 0.01% | -6.7% |
Q1 2020 | $1,890,000 | -27.5% | 39,980 | -7.4% | 0.02% | -11.8% |
Q4 2019 | $2,608,000 | -2.8% | 43,174 | -3.6% | 0.02% | -15.0% |
Q3 2019 | $2,682,000 | -66.5% | 44,769 | -64.0% | 0.02% | -67.2% |
Q2 2019 | $8,002,000 | -18.1% | 124,506 | +3.5% | 0.06% | -23.8% |
Q1 2019 | $9,769,000 | +249.5% | 120,347 | +132.8% | 0.08% | +196.3% |
Q4 2018 | $2,795,000 | +6.0% | 51,696 | +1.1% | 0.03% | +17.4% |
Q3 2018 | $2,638,000 | +22.4% | 51,142 | -1.1% | 0.02% | +9.5% |
Q2 2018 | $2,155,000 | -0.7% | 51,708 | +5.0% | 0.02% | -4.5% |
Q1 2018 | $2,171,000 | -11.7% | 49,247 | +0.8% | 0.02% | -15.4% |
Q4 2017 | $2,458,000 | +12.6% | 48,872 | +13.5% | 0.03% | +4.0% |
Q3 2017 | $2,183,000 | -17.9% | 43,054 | -17.6% | 0.02% | -24.2% |
Q2 2017 | $2,659,000 | +33.1% | 52,263 | +5.2% | 0.03% | +22.2% |
Q1 2017 | $1,998,000 | -5.9% | 49,690 | +12.0% | 0.03% | -15.6% |
Q4 2016 | $2,123,000 | +83.2% | 44,376 | +40.3% | 0.03% | +60.0% |
Q3 2016 | $1,159,000 | -6.4% | 31,638 | -40.5% | 0.02% | -20.0% |
Q2 2016 | $1,238,000 | +22.3% | 53,152 | +112.8% | 0.02% | -7.4% |
Q1 2016 | $1,012,000 | +391.3% | 24,981 | +652.4% | 0.03% | +440.0% |
Q4 2015 | $206,000 | – | 3,320 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Bellevue Group AG | 9,930,245 | $396,117,000 | 3.87% |
Sicart Associates LLC | 368,409 | $14,696,000 | 3.50% |
Camber Capital Management LP | 2,000,000 | $79,780,000 | 2.69% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 181,781 | $7,251,000 | 1.91% |
SECTOR GAMMA AS | 263,488 | $10,511,000 | 1.86% |
Parkman Healthcare Partners LLC | 136,380 | $5,440,000 | 1.19% |
Eversept Partners, LP | 442,000 | $17,631,380 | 1.18% |
Affinity Asset Advisors, LLC | 75,000 | $2,992,000 | 1.07% |
TANAKA CAPITAL MANAGEMENT INC | 16,661 | $665,000 | 0.90% |
Sonora Investment Management, LLC | 168,665 | $6,728,000 | 0.88% |